Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma.

Patients living with severe asthma (SA) experience multiple health-related quality of life (HRQoL) impairments. This study examined HRQoL changes after biologic treatment initiation among a large, real-world cohort of patients with SA. CHRONICLE is an ongoing observational study of subspecialist-treated adults with SA who receive biologics or maintenance systemic corticosteroids or are uncontrolled on high-dosage inhaled corticosteroids with additional controllers. Patients enrolled February 2018-February 2023 were asked to complete the St. George's Respiratory Questionnaire (SGRQ) every 6 months (total score range of 0-100 [0=best possible health], meaningful change threshold is a 4-unit reduction in the total score). Changes in SGRQ responses from 6 months before initiation to 12 to 18 months after initiation were summarized. A total of 76 patients completed the SGRQ 0 to 6 months before and 12 to 18 months after biologic initiation. The mean (SD) SGRQ total score decreased from 52.2 (20.6) to 41.9 (23.8), with improvement across the symptoms (-14.5), activity (-11.0), and impacts (-8.3) components. For specific impairments reported by ≥50% of patients before biologic initiation, fewer reported each impairment after biologic initiation; the largest reductions were for "Questions about what activities usually make you feel short of breath these days [Walking outside on level ground]" (67% to 43%), "Questions about other effects that your respiratory problems may have on you these days [I feel that I am not in control of my respiratory problems]" (55% to 34%), and "Questions about your cough and shortness of breath these days [My coughing or breathing disturbs my sleep]" (63% to 45%). In this real-world cohort of adults with SA, biologic initiation was associated with meaningful improvements in asthma-related HRQoL. These data provide further insight into the burden SA places on patients and the benefits of biologic treatment.

Informations de copyright

© 2024 Soong et al.

Déclaration de conflit d'intérêts

WS: Consultant – Amgen, AstraZeneca, Genentech, Regeneron, Sanofi, Novartis, Teva; speaker – Amgen, AstraZeneca, GSK, Regeneron, Sanofi; research – Amgen, AstraZeneca, Genentech, GSK, Incyte, Konseka, Pfizer, AbbVie, Upstream-Bio, Regeneron, Sanofi, Novartis. BEC: Advisory boards, consultant, and speaker – AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Regeneron, Sanofi Genzyme. WC: Speaker – AbbVie, Alladapt Immunotherapeutics, Blueprint Medicines, Bryn Pharma, Hikma Pharmaceuticals, Merck Sharp & Dohme LLC, Merz Pharmaceuticals, AstraZeneca, Teva, Boehringer Ingelheim, Regeneron, and Sanofi and Genzyme US Companies; consultant – AstraZeneca, Teva, Boehringer Ingelheim, Regeneron, Sanofi, Circassia, CSL Behring, Genentech, GlaxoSmithKline, Horizon Pharma, Kaleo, Mylan, Pfizer, Shire, Meda, Baxalta, Novartis, Greer Laboratories, Alcon Laboratories, Valeant Pharmaceuticals, Grifols, Optinose, Aerocrine. JT: Consultant and advisory boards – AstraZeneca. AP, NC: Employees and shareholders at the time this work was completed – AstraZeneca. DC, and CSA: Employees and shareholders – AstraZeneca.